Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi
The FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a rare vision-threatening autoimmune condition.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year